Background: The typical hearing loss described among diabetes patients is progressive, bilateral, sensorineural deafness of gradual onset that predominantly affects the higher frequencies. Although there is mounting evidence for a relationship between diabetes and hearing impairment the awareness of auditory organ involvement in the course of diabetes is still not widespread among healthcare providers involved in diabetes care. Objective of present study was to assess the prevalence and the factors influencing sensorineural deafness among the patients with type II diabetes mellitus.Methods: A cross-sectional study was conducted at our hospital for a period of 6 months. All type II diabetes patients without any other major systemic illness (CVA, coronary artery disease, thyroid disorders) were included for the study. A total of 300 patients were included in our study and the informed consent was obtained from all the study participants. A detailed history related to hearing loss and diabetes status was elicited from all the patients. All basic blood investigations along with HbA1c was performed on all the patients. All the patients were subjected to pure tone audiometry and it was performed using a pure tone audiometer model AUL 12096 audiometer of Labat company in a sound proof room.Results: The total prevalence of sensori-neural deafness among the study subjects was found to be 51.3% with majority of them having mild to moderate degree of sensori-neural deafness. Increase in age, female gender, longer duration of diabetes and higher HbA1C levels are the factors which had influenced the state of sensorineural deafness among the study subjects.Conclusions: The use of audiological test at primary care level should be made mandate for screening all the diabetes patients for hearing loss such a way the quality of life can be improved for patients requiring therapeutic interventions for their hearing improvement.
Background: Atorvastatin is the most commonly used drug for the treatment of dyslipidaemia. Long term administration of statins helps in the reduction of cardiovascular morbidity and mortality associated with dyslipidaemia. Number of studies have shown that alternate day dosing of statins is efficacious and safe alternative to daily dosing. Objectives: To compare the efficacy and tolerability of daily & alternate day regimen of Atorvastatin in the treatment of naïve dyslipidaemic South Indian patients. Materials & Methods:It is an open labeled, prospective, parallel, comparative interventional study. Ninety patients satisfying the inclusion criteria were randomized in to group 1 (n=45) and group 2 (n=45) and received atorvastatin 10 mg daily and alternate days respectively for 3 months. Pretreatment and post treatment anthropometric measurements, biochemical and lipid parameters were recorded. Patients were followed at fortnightly intervals for 3 months to check the patient compliance and adherence to treatment. Data were analyzed by suitable statistical methods. Results: There was a statistically significant reduction of total cholesterol, triglycerides, LDL, VLDL and increase of HDL cholesterol in both groups. Post treatment between group comparison shows a significantly higher reduction of LDL in group 1 than group 2 patients. All other lipid parameters were significantly similar between the groups at 12 weeks follow-up. Daily and alternate day treatment were well tolerated by the patients of both the group and there was no untoward incident during the study period. Conclusion: Alternate day administration of atorvastatin causes a beneficial alternation of lipid parameters which helps in reducing the cost and adverse effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.